Literature DB >> 6800356

Interaction of factor VIII-von Willebrand Factor with phospholipid vesicles.

L O Andersson, J E Brown.   

Abstract

The interaction of Factor VIII-von Willebrand Factor with phospholipid vesicles has been studied by using sucrose-density-gradient ultracentrifugation. When purified Factor VIII-von Willebrand Factor was run alone. Factor VIII activity and Factor VIIIR-Ag sedimented together to the lower half of the tube. Addition of phosphatidylserine/phosphatidylethanolamine vesicles at concentrations above 250 microgram/ml resulted in complete separation of Factor VIII activity and Factor VIIIR-Ag, the former appearing with the phospholipid on the top of the tube and the latter sedimenting as before. This separation was obtained even in the presence of proteinase inhibitors. Activation of Factor VIII-von Willebrand Factor by thrombin resulted in formation of a slow sedimenting component containing essentially all the Factor VIII activity, whereas the Factor VIIIR-Ag sedimented towards the bottom of the tube as before. The thrombin-induced Factor VIII activity was strongly bound to phospholipid vesicles as determined by density-gradient centrifugations at various Factor VIII concentrations and low concentrations of phospholipid. Based on certain assumptions a dissociation constant of 2.5 nM was calculated, a mechanism for the formation in vivo of the Factor X-activator complex is suggested.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6800356      PMCID: PMC1163514          DOI: 10.1042/bj2000161

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  17 in total

1.  Importance of protease inhibition in studies on purified factor VIII (antihaemophilic factor).

Authors:  E A Beck; P Bachmann; P Barbier; M Furlan
Journal:  Thromb Haemost       Date:  1976-02-29       Impact factor: 5.249

2.  Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

3.  The adsorption of coagulation factors onto phospholipids. Its role in the reaction mechanism of blood coagulation.

Authors:  H C Hemker; M J Kahn; P P Devilee
Journal:  Thromb Diath Haemorrh       Date:  1970-10-31

4.  Separation of human factor VIII activity from the von Willebrand's antigen and ristocetin platelet aggregating activity.

Authors:  R Baugh; J Brown; R Sargeant; C Hougie
Journal:  Biochim Biophys Acta       Date:  1974-12-18

5.  Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity.

Authors:  H J Weiss; I W Hoyer
Journal:  Science       Date:  1973-12-14       Impact factor: 47.728

6.  Molecular forms of antihaemophilic globulin in plasma, cryoprecipitate and after thrombin activation.

Authors:  H J Weiss; S Kochwa
Journal:  Br J Haematol       Date:  1970-01       Impact factor: 6.998

7.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

8.  Factor VIII recombination after dissociation by CaCl12.

Authors:  H A Cooper; T R Griggs; R H Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

9.  Separation of sub-units of antihemophilic factor (AHF) by agarose gel chromatography.

Authors:  H J Weiss; L L Phillips; W Rosner
Journal:  Thromb Diath Haemorrh       Date:  1972-04-30

10.  Studies of the thromboplastic effect of human plasma lipoproteins.

Authors:  H Sandberg; L O Andersson
Journal:  Thromb Haemost       Date:  1976-02-29       Impact factor: 5.249

View more
  15 in total

1.  Proteolytic cleavage of recombinant two-chain factor VIII during cell culture production is mediated by protease(s) from lysed cells. The use of pulse labelling directly in production medium.

Authors:  K Hansen; M Kjalke; P B Rasmussen; L Kongerslev; M Ezban
Journal:  Cytotechnology       Date:  1997-09       Impact factor: 2.058

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

4.  Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.

Authors:  Justin D Walter; Rachel A Werther; Maria S Polozova; Julie Pohlman; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  J Biol Chem       Date:  2013-02-15       Impact factor: 5.157

5.  Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.

Authors:  D C Hill-Eubanks; C G Parker; P Lollar
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

Review 7.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain.

Authors:  Keiji Nogami; Midori Shima; John C Giddings; Masahiro Takeyama; Ichiro Tanaka; Akira Yoshioka
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

9.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

10.  Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.

Authors:  Shannon L Meeks; John F Healey; Ernest T Parker; Rachel T Barrow; Pete Lollar
Journal:  Blood       Date:  2008-05-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.